Hiroaki Wakimoto

20.1k total citations · 2 hit papers
185 papers, 9.4k citations indexed

About

Hiroaki Wakimoto is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Hiroaki Wakimoto has authored 185 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Molecular Biology, 71 papers in Oncology and 70 papers in Genetics. Recurrent topics in Hiroaki Wakimoto's work include Virus-based gene therapy research (65 papers), Glioma Diagnosis and Treatment (48 papers) and CAR-T cell therapy research (41 papers). Hiroaki Wakimoto is often cited by papers focused on Virus-based gene therapy research (65 papers), Glioma Diagnosis and Treatment (48 papers) and CAR-T cell therapy research (41 papers). Hiroaki Wakimoto collaborates with scholars based in United States, Japan and China. Hiroaki Wakimoto's co-authors include Samuel D. Rabkin, Robert L. Martuza, Khalid Shah, Daniel P. Cahill, William T. Curry, Masaru Aoyagi, David N. Louis, E. Antonio Chiocca, Ryuichi Kanai and Jianfang Ning and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Hiroaki Wakimoto

177 papers receiving 9.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

2019 426 citations Brian V. Nahed, Daniel P. Cahill et al. profile →
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

2015 376 citations Rachel Litman Flynn, Maya Jeitany et al. Science profile →

Peers

Countries citing papers authored by Hiroaki Wakimoto

Since Specialization

Citations

This map shows the geographic impact of Hiroaki Wakimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Wakimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Wakimoto more than expected).

Fields of papers citing papers by Hiroaki Wakimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Wakimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Wakimoto. The network helps show where Hiroaki Wakimoto may publish in the future.

Co-authorship network of co-authors of Hiroaki Wakimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Wakimoto. A scholar is included among the top collaborators of Hiroaki Wakimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Wakimoto. Hiroaki Wakimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combination therapy of adagrasib and abemaciclib in non-small cell lung cancer brain metastasis models genomically characterized by KRAS-G12C and homozygous loss of CDKN2A 2025 ·Acta Neuropathologica Communications ·(unknown), (unknown), Consuelo Torrini, Fatma Turna Demir, Naema Nayyar, (unknown), Y. Ishikawa, (unknown), (unknown), (unknown), Lisa Rahbæk, (unknown), Jill Hallin, Priscilla K. Brastianos, Hiroaki Wakimoto	2
2	Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair 2020 ·Clinical Cancer Research ·Fumi Higuchi, Hiroaki Nagashima, Jianfang Ning, Mara V.A. Koerner, Hiroaki Wakimoto, Daniel P. Cahill	88
3	The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA -Mutant Breast Cancer Brain Metastases 2019 ·Clinical Cancer Research ·Franziska M. Ippen, Christopher Alvarez‐Breckenridge, Benjamin M. Kuter, Alexandria L. Fink, Ivanna V. Bihun, Matthew Lastrapes, Tristan Penson, Stephen Schmidt, Gregory R. Wojtkiewicz, Jianfang Ning, Megha Subramanian, Anita Giobbie‐Hurder, María Martínez-Lage, Scott L. Carter, Daniel P. Cahill, Hiroaki Wakimoto, Priscilla K. Brastianos	61
4	Identification of SERPINE1 as a Regulator of Glioblastoma Cell Dispersal with Transcriptome Profiling 2019 ·Cancers ·Fidan Seker-Polat, Ahmet Cingöz, İlknur Sur‐Erdem, (unknown), (unknown), (unknown), Myvizhi Esai Selvan, Zeynep H. Gümüş, Mehmet Gönen, Halil Bayraktar, Hiroaki Wakimoto, Tugba Bagcı-Önder	46
5	Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models 2018 ·Clinical Cancer Research ·Dipongkor Saha, Hiroaki Wakimoto, Cole W. Peters, (unknown), Samuel D. Rabkin, Robert L. Martuza	59
6	PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency–Mediated Acquired Resistance to Temozolomide 2018 ·Molecular Cancer Therapeutics ·Fumi Higuchi, Alexandria L. Fink, Juri Kiyokawa, Julie J. Miller, Mara V.A. Koerner, Daniel P. Cahill, Hiroaki Wakimoto	28
7	Emerging Medical Treatments for Meningioma in the Molecular Era 2018 ·Biomedicines ·Fares Nigim, Hiroaki Wakimoto, Ekkehard M. Kasper, Linda Ackermans, Yasin Temel	31
8	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1 -Mutant Cancers and Potentiates NAD+ Depletion–Mediated Cytotoxicity 2017 ·Cancer Research ·Kensuke Tateishi, Fumi Higuchi, Julie J. Miller, Mara V.A. Koerner, Nina Lelic, Ganesh M. Shankar, Shota Tanaka, David E. Fisher, Tracy T. Batchelor, A. John Iafrate, Hiroaki Wakimoto, S. Andrew, Daniel P. Cahill	73
9	Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas 2017 ·Proceedings of the National Academy of Sciences ·Wanlu Du, Ivan Seah, (unknown), (unknown), Katrina Meeth, Marcus Bosenberg, Hiroaki Wakimoto, David E. Fisher, Khalid Shah	100
10	Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma 2016 ·Clinical Cancer Research ·Kensuke Tateishi, A. John Iafrate, Quan Ho, William T. Curry, Tracy T. Batchelor, Keith T. Flaherty, Maristela L. Onozato, Nina Lelic, (unknown), Daniel P. Cahill, S. Andrew, Hiroaki Wakimoto	119
11	Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors breakdown → 2015 ·Science ·Rachel Litman Flynn, (unknown), Maya Jeitany, Hiroaki Wakimoto, Alysia R. Bryll, Neil J. Ganem, Francesca Bersani, José Ramón Pineda, Mario L. Suvà, Cyril H. Benes, Daniel A. Haber, François D. Boussin, Lee Zou	376
12	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH -Mutant Gliomas 2014 ·Clinical Cancer Research ·Hiroaki Wakimoto, Shota Tanaka, William T. Curry, Franziska Loebel, Dan Zhao, Kensuke Tateishi, Juxiang Chen, (unknown), Nina Lelic, James C. Kim, Dora Dias‐Santagata, Leif W. Ellisen, Darrell R. Borger, Sarah‐Maria Fendt, Matthew G. Vander Heiden, Tracy T. Batchelor, A. John Iafrate, Daniel P. Cahill, S. Andrew	130
13	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression 2014 ·Cancer Discovery ·James P. Sullivan, Brian V. Nahed, Marissa W. Madden, (unknown), Simeon Springer, Deepak Bhere, S. Andrew, Hiroaki Wakimoto, S. Michael Rothenberg, Lecia V. Sequist, Ravi Kapur, Khalid Shah, A. John Iafrate, William T. Curry, Jay S. Loeffler, Tracy T. Batchelor, David N. Louis, Mehmet Toner, Shyamala Maheswaran, Daniel A. Haber	200
14	Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma 2014 ·Science ·Anoop P. Patel, Itay Tirosh, John J. Trombetta, Alex K. Shalek, Shawn Gillespie, Hiroaki Wakimoto, Daniel P. Cahill, Brian V. Nahed, William T. Curry, R L Martuza, David N. Louis, Orit Rozenblatt–Rosen, Mario L. Suvà, Aviv Regev, B Bernstein	186
15	Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts 2011 ·Clinical Cancer Research ·Tooba A. Cheema, Ryuichi Kanai, (unknown), Hiroaki Wakimoto, Brent J. Passer, Samuel D. Rabkin, Robert L. Martuza	70
16	YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth 2011 ·Cancer Research ·Abbas Fotovati, (unknown), (unknown), Loic P. Deleyrolle, Cathy Lee, Joanna Triscott, James Y. Chen, Sonia Franciosi, Yasuhiro Nakamura, Yasuo Sugita, Takeshi Uchiumi, Michihiko Kuwano, Blair R. Leavitt, Sheila K. Singh, Alexa Jury, Chris Jones, Hiroaki Wakimoto, Brent A. Reynolds, Catherine J. Pallen, Sandra E. Dunn	69
17	A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells 2011 ·Clinical Cancer Research ·Ryuichi Kanai, Hiroaki Wakimoto, Robert L. Martuza, Samuel D. Rabkin	68
18	Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication 2010 ·Cancer Research ·Brent J. Passer, Tooba A. Cheema, Bingsen Zhou, Hiroaki Wakimoto, Cécile Zaupa, (unknown), (unknown), Shulin Wu, Chin‐Lee Wu, James W. Noah, Qianjun Li, John K. Buolamwini, Yun Yen, Samuel D. Rabkin, Robert L. Martuza	26
19	A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models 2010 ·Cancer Research ·Tugba Bagcı-Önder, Hiroaki Wakimoto, Maarten Anderegg, (unknown), Khalid Shah	88
20	Human Glioblastoma–Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors 2009 ·Cancer Research ·Hiroaki Wakimoto, Santosh Kesari, Christopher J. Farrell, William T. Curry, Cécile Zaupa, Manish K. Aghi, Toshihiko Kuroda, Anat Stemmer‐Rachamimov, Khalid Shah, Ta‐Chiang Liu, Deva S. Jeyaretna, Jason Debasitis, Jan Pruszak, Robert L. Martuza, Samuel D. Rabkin	279

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact